The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Implementing precision oncology in pancreatic cancer
Nelson Dusetti, PhD, Cancer Research Centre of Marseille, Marseille, France, shares remaining challenges in the implementation of precision medicine approaches for patients with pancreatic cancer. The heterogeneity between tumors and within each tumor presents challenges in identifying effective treatments. Artificial intelligence, single-cell analysis, transcriptomic, and molecular analysis are key tools in understanding intratumoral heterogeneity. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Predicting Med
Patents, Royalties, Other Intellectual Property – PCT/EP2022/065222. Simple transcriptomic signatures to determine chemosensitivity for pancreatic ductal adenocarcinoma. SATT Sud-Est. Inventors: N. Dusetti, N. Fraunhoffer, J. Iovanna, 2021. Licensing to Predicting Med.
